{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03958474",
            "orgStudyIdInfo": {
                "id": "47844"
            },
            "secondaryIdInfos": [
                {
                    "id": "R01DA047368",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/R01DA047368"
                }
            ],
            "organization": {
                "fullName": "University of Kentucky",
                "class": "OTHER"
            },
            "briefTitle": "Neurobehavioral Mechanisms of Choice in Opioid Use Disorder",
            "officialTitle": "Neurobehavioral Mechanisms of Choice in Opioid Use Disorder",
            "therapeuticArea": [
                "Other"
            ],
            "study": "neurobehavioral-mechanisms-of-choice-in-opioid-use-disorder"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2019-08-16",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-03-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-03-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2019-05-16",
            "studyFirstSubmitQcDate": "2019-05-18",
            "studyFirstPostDateStruct": {
                "date": "2019-05-22",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-01-10",
            "lastUpdatePostDateStruct": {
                "date": "2024-01-12",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "Joshua A. Lile, Ph.D.",
                "investigatorTitle": "Professor",
                "investigatorAffiliation": "University of Kentucky"
            },
            "leadSponsor": {
                "name": "Joshua A. Lile, Ph.D.",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Institute on Drug Abuse (NIDA)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The objective of this protocol is to use probabilistic reinforcement learning choice tasks and magnetic resonance neuroimaging to demonstrate the impact of problematic opioid use and opioid withdrawal on dynamic decision-making and reveal the neurobehavioral and neurobiological processes underlying abnormal task performance. A second objective is to identify an appropriate dose of intravenous remifentanil for subsequent studies in physically dependent individuals with opioid use disorder."
        },
        "conditionsModule": {
            "conditions": [
                "Opioid Use Disorder"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "EARLY_PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "CROSSOVER",
                "interventionModelDescription": "Within-subjects design",
                "primaryPurpose": "BASIC_SCIENCE",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "maskingDescription": "Double-blind",
                    "whoMasked": [
                        "PARTICIPANT",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 31,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Active treatment followed by placebo treatment",
                    "type": "EXPERIMENTAL",
                    "description": "Participants complete a gambling task during oxycodone administration and then complete the same gambling task during placebo administration. Participants with a history of IV opioid use can opt to complete a final remifentanil dose-ranging session.",
                    "interventionNames": [
                        "Drug: Oxycodone",
                        "Drug: Remifentanil"
                    ]
                },
                {
                    "label": "Placebo treatment followed by active treatment",
                    "type": "EXPERIMENTAL",
                    "description": "Participants complete a gambling task during placebo administration and then complete the same gambling task during oxycodone administration. Participants with a history of IV opioid use can opt to complete a final remifentanil dose-ranging session.",
                    "interventionNames": [
                        "Drug: Oxycodone",
                        "Drug: Remifentanil"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Oxycodone",
                    "description": "Participants receive oxycodone or placebo.",
                    "armGroupLabels": [
                        "Active treatment followed by placebo treatment",
                        "Placebo treatment followed by active treatment"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Remifentanil",
                    "description": "Participants with a history of IV opioid use can opt to complete a session in which they receive remifentanil.",
                    "armGroupLabels": [
                        "Active treatment followed by placebo treatment",
                        "Placebo treatment followed by active treatment"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Gambling task",
                    "description": "The number of monetary rewards earned on a gambling task, in which two options signaled by distinct cues are presented on a computer screen and choosing either could result in the delivery of money, but the reinforcement probabilities of the options differ, and change during the task.",
                    "timeFrame": "Change in monetary rewards earned on a gambling task as a function of the intervention will be assessed by administering this task once per session across two sessions during a 9-day inpatient enrollment in each subject"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Respiration rate",
                    "description": "Breaths per minute measured by capnography device",
                    "timeFrame": "Measured continuously during a single 2.5 hour session in which remifentanil is administered."
                },
                {
                    "measure": "End tidal carbon dioxide",
                    "description": "End tidal carbon dioxide measured by capnography device",
                    "timeFrame": "Measured continuously during a single 2.5 hour session in which remifentanil is administered."
                },
                {
                    "measure": "Oxygen saturation",
                    "description": "Blood oxygen concentration measured by capnography device",
                    "timeFrame": "Measured continuously during a single 2.5 hour session in which remifentanil is administered."
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Must meet moderate/severe criteria for moderate/severe opioid use disorder, report recent prescription or illicit opioid use, and be opioid dependent, as evidenced by either a urine sample positive for recent opioid use or being in frank withdrawal during screening.\n* Female subjects must be using an effective form of birth control (e.g., birth control pills, surgical sterilization, IUD, cervical cap with a spermicide, or abstinence).\n* Able to speak and read English\n* Subjects who are interested in completing the remifentanil dose-ranging session must report a history of intravenous opioid use and a baseline O2 saturation of 95% or greater.\n\nExclusion Criteria:\n\n* History of, or current, clinically significant physical disease (e.g., respiratory disease \\[asthma, COPD, sleep apnea\\], impaired cardiovascular functioning, seizure disorder or CNS tumors) or current or past history of psychiatric disorder that would limit compliance in the studies, other than substance use disorder.\n* Meet diagnostic criteria for psychoactive substance use disorder for substances other than opioids (OUD subjects only) or nicotine that would require detoxification (i.e., alcohol, benzodiazepines or barbiturates).\n* Contraindications for MRI scanning (e.g., pacemaker, metal implants, claustrophobia, or any other implanted medical device).\n* Vision or hearing problems that would preclude completion of experimental tasks.\n* At risk for respiratory complications and have predictors of difficult bag mask ventilation (e.g., dentures, very full beard), in case emergency respiratory intervention is needed.\n* Seeking treatment for SUD.\n* Poor venous access (only subjects who will participate in the remifentanil dose-ranging session).",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "50 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "JOSHUA LILE, Ph.D.",
                    "role": "CONTACT",
                    "phone": "8593236034",
                    "email": "jalile2@uky.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "JOSHUA LILE, Ph.D.",
                    "affiliation": "University of Kentucky",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Laboratory of Human Behavioral Pharmacology",
                    "status": "RECRUITING",
                    "city": "Lexington",
                    "state": "Kentucky",
                    "zip": "40536-0086",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Frances Wagner, RN",
                            "role": "CONTACT",
                            "phone": "859-257-5388",
                            "email": "fpwagn2@uky.edu"
                        },
                        {
                            "name": "Joshua A. Lile, Ph.D.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.98869,
                        "lon": -84.47772
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009293",
                    "term": "Opioid-Related Disorders"
                },
                {
                    "id": "D000019966",
                    "term": "Substance-Related Disorders"
                }
            ],
            "ancestors": [
                {
                    "id": "D000079524",
                    "term": "Narcotic-Related Disorders"
                },
                {
                    "id": "D000064419",
                    "term": "Chemically-Induced Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12244",
                    "name": "Opioid-Related Disorders",
                    "asFound": "Opioid Use Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21837",
                    "name": "Substance-Related Disorders",
                    "asFound": "Opioid Use Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2057",
                    "name": "Narcotic-Related Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M30302",
                    "name": "Chemically-Induced Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC25",
                    "name": "Substance Related Disorders"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000077208",
                    "term": "Remifentanil"
                },
                {
                    "id": "D000010098",
                    "term": "Oxycodone"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000701",
                    "term": "Analgesics, Opioid"
                },
                {
                    "id": "D000009294",
                    "term": "Narcotics"
                },
                {
                    "id": "D000002492",
                    "term": "Central Nervous System Depressants"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000000700",
                    "term": "Analgesics"
                },
                {
                    "id": "D000018689",
                    "term": "Sensory System Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4033",
                    "name": "Analgesics, Opioid",
                    "relevance": "LOW"
                },
                {
                    "id": "M1696",
                    "name": "Remifentanil",
                    "asFound": "Emergency",
                    "relevance": "HIGH"
                },
                {
                    "id": "M13020",
                    "name": "Oxycodone",
                    "asFound": "Where",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4032",
                    "name": "Analgesics",
                    "relevance": "LOW"
                },
                {
                    "id": "M12245",
                    "name": "Narcotics",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}